Aiming to catch Alnylam, AstraZeneca & Ionis plan FDA filing for rare disease drug

The planned FDA submission follows the report from AstraZeneca and Ionis Pharmaceuticals that their partnered drug, eplontersen, met the main goals of a pivotal study in treating nerve pain caused by hereditary transthyretin-mediated amyloidosis. The data come one week after rival Alnylam Pharmaceuticals won FDA approval for its second drug for this rare disease.

Leave a Reply

Your email address will not be published.